Literature DB >> 12707316

Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.

Thomas Schüler1, Thomas Blankenstein.   

Abstract

CD8(+) effector T cells recognize malignant cells by monitoring their surface for the presence of tumor-derived peptides bound to MHC class I molecules. In addition, tumor-derived Ags can be cross-presented to CD8(+) effector T cells by APCs. IFN-gamma production by CD8(+) T cells is often critical for tumor rejection. However, it remained unclear whether 1) CD8(+) T cells secrete IFN-gamma in response to Ag recognition on tumor cells or APCs and 2) whether IFN-gamma mediates its antitumor effect by acting on host or tumor cells. We show in this study that CD8(+) effector T cells can reject tumors in bone marrow-chimeric mice incapable of cross-presenting Ag by bone marrow-derived APCs and that tumor rejection required host cells to express IFN-gammaR. Together, CD8(+) effector T cells recognize Ag directly on tumor cells, and this recognition is sufficient to reject tumors by IFN-gamma acting on host cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707316     DOI: 10.4049/jimmunol.170.9.4427

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.

Authors:  Giuliana P Mognol; Roberto Spreafico; Victor Wong; James P Scott-Browne; Susan Togher; Alexander Hoffmann; Patrick G Hogan; Anjana Rao; Sara Trifari
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-10       Impact factor: 11.205

Review 2.  The role of salt for immune cell function and disease.

Authors:  Ralf Willebrand; Markus Kleinewietfeld
Journal:  Immunology       Date:  2018-03-24       Impact factor: 7.397

3.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

4.  Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

Authors:  Béatrice Breart; Fabrice Lemaître; Susanna Celli; Philippe Bousso
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.

Authors:  Bent Rubin; Joëlle Riond; Laetitia Courtiade; Nicolas Roullet; Jean-Edouard Gairin
Journal:  Cancer Immun       Date:  2008-09-11

6.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

7.  Fas expression by tumor stroma is required for cancer eradication.

Authors:  Joanna J Listopad; Thomas Kammertoens; Kathleen Anders; Bjoern Silkenstedt; Gerald Willimsky; Karin Schmidt; Anja A Kuehl; Christoph Loddenkemper; Thomas Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

8.  Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.

Authors:  Margaret Gil; Magdalena Bieniasz; Andrzej Wierzbicki; Barbara J Bambach; Hanna Rokita; Danuta Kozbor
Journal:  J Immunol       Date:  2009-10-21       Impact factor: 5.422

9.  IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses.

Authors:  Shana M Coley; Mandy L Ford; Samantha C Hanna; Maylene E Wagener; Allan D Kirk; Christian P Larsen
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

10.  MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.

Authors:  Carolina M Soto; Jennifer D Stone; Adam S Chervin; Boris Engels; Hans Schreiber; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2012-08-25       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.